Bladder Cancer: Eight-Market Drug Forecast And Market Analysis

Common bladder cancer market drivers across the 8MM include:

• The sales of Padcev represent the most high-profile driver totaling $3.6 billion in 2033.
• Newly approved and pipeline agents, such as Adstiladrin, TAR200, and cretostimogene grenadenorepvec, aimed at improving outcomes for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), are key market drivers.
• Several late-stage pipeline drugs with novel MOAs have received orphan drug designation from the FDA. As such, they are granted a potential seven years of market exclusivity after approval.

Common barriers to market growth experienced across the 8MM include:

• Future patent expiry of key players, such as Keytruda and Opdivo, could introduce an influx of lower-cost and effective biosimilars, further escalating the competition in the space.
• Implementing gene therapy into a urology practice poses challenges in terms of storage and handling requirements as well as the specialized training required to administer these products.
• Higher costs of therapy for newly approved and pipeline agents will impact reimbursement in NMIBC, which has a large market size, and has traditionally been treated with low-cost chemotherapy and BCG.

Key Highlights

• Report deliverables include a Pdf report and Excel-based forecast model
• Forecasts includes the 8MM
• Forecasts covers from 2023-2033
• The analyst valued the bladder cancer market in the 8MM at $3 billion in 2023 and expects the market to increase to $16 billion by 2033
• In the base year, 2023, immunotherapy drugs contributed the highest sales, 61%, to the bladder cancer market. The current main immunotherapies used in bladder cancer are the ICIs Keytruda, Opdivo, and Bavencio, and the recently approved immunostimulant Anktiva (for NMIBC).
• The class of ADCs, which includes Padcev, Enhertu, Trodelvy, and Aidix, was the second largest contributor, taking 23% of the bladder cancer market in 2023, and is expected to grow throughout the forecast period.
• Gene therapy is anticipated to triple from 4% of the total market in 2023 to 12% in 2033. The rapid adoption rate of Adstiladrin and upcoming product launches are due to the drug class’s primary indication, second-line treatment in high-risk NMIBC, an area of high unmet need.

Scope

• Overview of bladder cancer, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized bladder cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the bladder cancer therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bladder cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
• Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships